A randomized study of tenofovir disoproxil fumarate in treatment- experienced HIV-1 infected adolescents

Pediatric Infectious Disease Journal

Volumn 31, Issue 5, 2012, Pages 469-473

  Negra, Marinella Della ^a   De Carvalho, Aroldo Prohmann ^b   De Aquino, Maria Zilda ^c   Da Silva, Marcos Tadeu Nolasco ^d   Pinto, Jorge ^e   White, Kirsten ^f   Arterburn, Sarah ^f   Liu, Ya Pei ^f   Enejosa, Jeffrey V ^g   Cheng, Andrew K ^f   Chuck, Steven L ^f   Rhee, Martin S ^f  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b HOSPITAL INFANTIL JOANA DE GUSMÃO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^f GILEAD SCIENCES   (United States)

^g Dynavax Technologies Corporation   (United States)

Author keywords

Adolescent; Antiretroviral therapy; HIV; Tenofovir

Indexed keywords

ABACAVIR; AMPHOTERICIN B; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; SAQUINAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CRYPTOCOCCOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VOMITING;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 84862803868     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824bf239     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. HIV Surveillance Report 2008. Vol. 20. Available at: http://www.cdc.gov/hiv/surveillance/resources/reports/ 2008report/pdf/2008SurveillanceReport.pdf. Accessed November 1, 2010.
2. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
3. Gallant JE, DeJesus E, Arribas JR, et al.; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
4. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985;106:522-526.
5. Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259-263.
6. HIV French Resistance. HIV-1 genotypic drug resistance interpretation's algorithms. Available at: http://www.hivfrenchresistance.org/tab2008.html. Accessed November 1, 2010.
7. Dawson J. Comparing treatment groups on the basis of slopes, areas-underthe-curve, and other summary measures. Drug Inf J. 1994;28:723-732.
8. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999;282:2305-2312.
9. Katlama C, Haubrich R, Lalezari J, et al.; DUET-1, DUET-2 study groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23:2289-2300.
10. O'Brien KO, Razavi M, Henderson RA, et al. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr. 2001;73:821-826.
11. Zuccotti G, Vigan̈ A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010;46:1633-1638.
12. Mora S, Sala N, Bricalli D, et al. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15:1823-1829.
13. Mora S, Zamproni I, Giacomet V, et al. Analysis of bone mineral content in horizontally HIV-infected children na?e to antiretroviral treatment. Calcif Tissue Int. 2005;76:336-340.
14. Mora S, Zamproni I, Beccio S, et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89:24-28.
15. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718.
16. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152:582-584.
17. Giacomet V, Mora S, Martelli L, et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:448-450.
18. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116:e846-e854.
19. Riordan A, Judd A, Boyd K, et al.; Collaborative HIV Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 2009;28:204-209.
20. Food and Drug Administration. Clinical review. March 2010. Available at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM209151.pdf. Accessed June 1, 2011.
21. Nelson RM, Lewis LL, Struble K, et al. Ethical and regulatory considerations for the inclusion of adolescents in HIV biomedical prevention research. J Acquir Immune Defic Syndr. 2010;54(suppl 1):S18-S24.